Partnership researching genetics and treatments of long COVID

pharmafile | May 11, 2022 | News story | Research and Development  

PrecisionLife Limited have announced a partnership with Sano Genetics, a genetic research platform enabling patients to participate in ethical research projects, to advance understanding of long-term effects of coronavirus infection (long COVID).

PrecisionLife is a global techbio company, which uses its deep insights into disease biology and patient stratification to drive precision medicine in chronic diseases. The company’s combinatorial analytics platform is uniquely able to identify the drivers of complex disease biology at an unprecedented level of resolution.

Dr Patrick Short, CEO and co-founder of Sano Genetics, said: “Learning to live with COVID and manage its health consequences has long term public health and economic implications. An estimated 1.7 million people in the UK have reported experiences of long COVID, with symptoms lasting longer than four weeks.”

The project will include analysis of Sano Genetics’ data from 3,000 UK adults suffering long COVID symptoms, using PrecisionLife’s proprietary combinatorial analytics platform to identify risk-factors and potential drug targets.

“Understanding how our genetics influence our response to COVID-19 is key to better protecting vulnerable people and developing effective treatments,” Dr Short continued, “PrecisionLife’s analysis of Sano Genetics’ data will enable this deep biological understanding.”

Dr Steve Gardner, CEO of PrecisionLife, said: “Long COVID is a major public health issue. Most sufferers have no clear path for engaging with the healthcare system, as diagnosis is uncertain and the complex symptoms and causes of the disease are not yet fully understood. In our 2020 study, we noted a range of cardiovascular, immunological, and neurological changes in COVID-19 patients and want to understand whether these are transient or permanent.”

It is estimated that 5-30% of COVID patients will go on to have long-term complications.

“We are confident that this study into the long-term effects of SARS-CoV-2 infection, working in partnership with Sano Genetics, will deliver valuable insights to enable a better understanding of long COVID vulnerabilities and ultimately ensure that personalized treatments are directed towards those patients that need them most.”

Ana Ovey

Related Content

No items found

Latest content